225 related articles for article (PubMed ID: 26286880)
21. Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer.
Einerhand SMH; Black AJ; Zargar H; Fairey AS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobson NE; Montgomery JS; Vasdev N; Yu EY; Xylinas E; Kassouf W; Dall'Era MA; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Garcia JA; Stephenson AJ; Shah JB; Daneshmand S; Zargar-Shoshtari K; Spiess PE; van Rhijn BWG; Black PC; Mertens LS
World J Urol; 2022 Nov; 40(11):2707-2715. PubMed ID: 36169695
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience.
Lemiński A; Kaczmarek K; Byrski T; Słojewski M
PLoS One; 2021; 16(11):e0259526. PubMed ID: 34731219
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
24. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1?
Zargar H; Zargar-Shoshtari K; Lotan Y; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black P;
J Urol; 2016 Apr; 195(4 Pt 1):886-93. PubMed ID: 26521718
[TBL] [Abstract][Full Text] [Related]
25. Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and Survival.
Patel HD; Patel SH; Blanco-Martinez E; Kuzbel J; Chen VS; Druck A; Koehne EL; Patel PM; Doshi CP; Hahn NM; Hoffman-Censits JH; Berg S; Bivalacqua TJ; Kates M; Quek ML
J Urol; 2022 Jan; 207(1):77-85. PubMed ID: 34445890
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience.
Iyer G; Tully CM; Zabor EC; Bochner BH; Dalbagni G; Herr HW; Donat SM; Russo P; Ostrovnaya I; Regazzi AM; Milowsky MI; Rosenberg JE; Bajorin DF
Clin Genitourin Cancer; 2020 Oct; 18(5):387-394. PubMed ID: 32273235
[TBL] [Abstract][Full Text] [Related]
27. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN
World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294
[TBL] [Abstract][Full Text] [Related]
28. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
29. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience.
Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
BJU Int; 2019 Jun; 123(6):1011-1019. PubMed ID: 30623554
[TBL] [Abstract][Full Text] [Related]
30. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
Matsui Y; Nishiyama H; Watanabe J; Teramukai S; Ono Y; Ohshima S; Fujimoto K; Hirao Y; Fukushima M; Ogawa O
Int J Clin Oncol; 2005 Apr; 10(2):133-8. PubMed ID: 15864700
[TBL] [Abstract][Full Text] [Related]
31. Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience.
Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Tarrel R; Quevedo FJ; Cheville JC; Karnes RJ
World J Urol; 2019 Nov; 37(11):2409-2418. PubMed ID: 30805684
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant chemotherapy is possibly beneficial for locally advanced or node-positive bladder cancer.
Kanatani A; Nakagawa T; Kawai T; Naito A; Sato Y; Yoshida K; Nozaki K; Nagata M; Yamada Y; Azuma T; Suzuki M; Fujimura T; Fukuhara H; Nishimatsu H; Kume H; Igawa Y; Homma Y
Clin Genitourin Cancer; 2015 Apr; 13(2):e107-12. PubMed ID: 25456839
[TBL] [Abstract][Full Text] [Related]
33. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.
Mertens LS; Meijer RP; Meinhardt W; van der Poel HG; Bex A; Kerst JM; van der Heijden MS; Bergman AM; Horenblas S; van Rhijn BW
BJU Int; 2014 Jul; 114(1):67-74. PubMed ID: 24053889
[TBL] [Abstract][Full Text] [Related]
34. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients.
Thompson RH; Boorjian SA; Kim SP; Cheville JC; Thapa P; Tarrel R; Dronca R; Costello B; Frank I
BJU Int; 2014 May; 113(5b):E17-21. PubMed ID: 24006893
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder.
Scosyrev E; Messing EM; van Wijngaarden E; Peterson DR; Sahasrabudhe D; Golijanin D; Fisher SG
Cancer; 2012 Jan; 118(1):72-81. PubMed ID: 21720989
[TBL] [Abstract][Full Text] [Related]
36. A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy.
Zargar-Shoshtari K; Zargar H; Lotan Y; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
J Urol; 2016 Jan; 195(1):53-9. PubMed ID: 26205531
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant Chemotherapy Does Not Increase the Morbidity of Radical Cystectomy: A 10-year Retrospective Nationwide Study.
Salminen AP; Koskinen I; Perez IM; Hurme S; Murtola TJ; Vaarala MH; Nykopp TK; Seppänen M; Isotalo T; Marttila T; Levomäki L; Becker S; Anttinen M; Liukkonen T; Säily M; Pogodin-Hannolainen D; Viitanen J; Palmberg C; Ottelin J; Sairanen J; Ettala OO; Boström PJ
Eur Urol Oncol; 2018 Dec; 1(6):525-530. PubMed ID: 31158099
[TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer.
Aydin AM; Cheriyan SK; Reich R; Hajiran A; Peyton CC; Zemp L; Yu A; Li R; Poch MA; Spiess PE; Jain R; Zhang J; Sexton WJ; Gilbert SM
Urol Oncol; 2022 Oct; 40(10):453.e19-453.e26. PubMed ID: 35811208
[TBL] [Abstract][Full Text] [Related]
39. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study.
Koga F; Kihara K; Fujii Y; Yoshida S; Saito K; Masuda H; Kageyama Y; Kawakami S
BJU Int; 2009 Jul; 104(2):189-94. PubMed ID: 19154452
[TBL] [Abstract][Full Text] [Related]
40. [Impact of neoadjuvant chemotherapy on the peri-operative morbidity of radical cystectomy for muscle invasive bladder cancer].
Michel C; Vordos D; Dumont C; Basset V; Meyer F; Gaudez F; Meria P; Cortesse A; Mongiat-Artus P; de la Taille A; Culine S; Desgrandchamps F; Masson-Lecomte A
Prog Urol; 2018 Sep; 28(10):495-501. PubMed ID: 29997033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
